| Catalog No. | HY196066 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Isotype | IgG |
|---|
| Clone ID | ARGX-111 |
|---|
| Biological activity |
ARGX-111 binds to native MET with an EC 50 ranging from 0.1 nmol/L to 0.7 nmol/L, competes with HGF displaying an IC 50 of 1.3 nmol/L and an IMAX of 95% [1]. ARGX-111 inhibits HGF-induced MET autophosphorylation in A549 cells (IC 50 = 5.3 nmol/L, IMAX = 74%), inhibits MET autophosphorylation in both MKN-45 cells (IC 50 = 0.2 nmol/L, IMAX = 63%) and EBC-1 cells (IC 50 = 12.7 nmol/L, IMAX = 69%) [1]. ARGX-111 neutralizes the promigratory effect of HGF, inhibits HGF-dependent colony formation by 78% in A549 cells [1]. ARGX-111 (1-10 nM/L) inhibits HGF-induced branched tubule formation in SV40 T-antigen-transformed LOC human kidney epithelial cell spheroids [1]. ARGX-111 (0.1-100 h) promotes a rapid decrease in MET expression in MKN-45, EBC-1 and MDA-MB 231 cells [1]. ARGX-111 (24-48 h) does not promote receptor shedding but reduced total MET protein levels in MKN-45 cells [1]. ARGX-111 (0-1000 nM/L) induces dose-dependent lysis in MKN-45, NCI-H441, A549 cells [1]. ARGX-111 induces antibody-dependent cellular phagocytosis (ADCP) in MKN-45 and 786-O cells [1]. ARGX-111 (0-667 nM/L) promotes dose-dependent ADCC in ALDH-1-sorted MDA-MB-231, CRCM168, CRCM174, CRCM389 cells [1]. |
| Expression system |
Mammalian cells |
| Clonality |
Monoclonal |
| Target |
Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
P08581 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | ARGX-111, ARGX111, ARGX111 |
|---|
| Background | Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant). |
|---|
| References |
1. Hultberg A, et al. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. Cancer Res. 2015 Aug 15;75(16):3373-83. [HY196066]
2. V Morello, et al. Abstract P2-05-17: ARGX-111 depletes MET-expressing circulating tumor cells via enhanced ADCC, resulting in inhibition of metastasis. Cancer Res 15 February 2016; 76 (4_Supplement): P2–05–17. [HY196066] |
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
한국어
日本語
Español
Français
Русский
